Jagsonpal Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jagsonpal Pharmaceuticals submitted its Q1 FY26 unaudited results, showing profit after tax of Rs. 108.52 million, up sharply from Rs. 52.81 million in the year-ago quarter (a rise of roughly 105%). Profit before tax climbed to Rs. 144.31 million from Rs. 71.10 million, while total expenses grew about 22% YoY to Rs. 640.06 million, pointing to meaningful margin expansion. Basic EPS rose to Rs. 1.60 (from a restated Rs. 0.78). Statutory auditor Walker Chandiok & Co LLP issued an unqualified limited review report with no qualifications or emphasis-of-matter paragraphs. On the corporate-action side, the company allotted 127,850 shares under ESOP 2022 and granted 37,500 fresh stock options, while final dividend of Rs. 2.5 per share has been recommended for FY25. Post-quarter, CFO Sachin Jain ceased to be a Key Managerial Personnel after being released during probation, and the company is in the process of appointing a new CFO.
The sharp YoY jump in profit, well ahead of expense growth, signals strong operating leverage and likely positive momentum for the stock; however, investors should keep an eye on the CFO transition and any disruption in financial reporting continuity.